Programs
- M. Tech. in Automotive Engineering -
- Fellowship In Interventional Pulmonology and Pulmonary Critical care - Fellowship
Publication Type : Journal Article
Publisher : Pulmonary Circulation
Source : Pulmonary Circulation, 2024 Jan 10;14(1):e12335. DOI: 10.1002/pul2.12335.
Url : https://pubmed.ncbi.nlm.nih.gov/38213946/
Keywords : Bmpr2 mutation, hereditary, imatinib, pulmonary hypertension
Campus : Kochi
School : School of Medicine
Department : Paediatric Cardiology
Year : 2024
Abstract : Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.
Cite this Research Publication : Kumar S, Biswas L, Pushkaran AC, Kumar RK, "BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension," Pulmonary Circulation, 2024 Jan 10;14(1):e12335. DOI: 10.1002/pul2.12335.